MediPharm Reminds Shareholders to Vote in Advance of June 13 DeadlineShareholders Urged to Vote for Proven Strategy and Team, Reject Dissident’s Inadequate Plan and Nominees
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special MeetingTORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the application (CV-25-00743454-00CL) (the “Application”) issued by Apollo Technology Capital Corporation (“Apollo”) and Nobul Technologies Inc. (together with Apollo, the “Applicants”) against the Company on May 16, 2025 (the “Notice”).
MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee FacilityTORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm"), a pharmaceutical company specialized in precision-based cannabinoids, announced the closing of the sale of its Hope, British Columbia facility (the “Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”). In parallel, the Company is expanding annual international cultivation capacity at its EU GMP-certified facility in Napanee, Ontario (the “Napanee Facility”) by approximately 30% in 2025.
MediPharm Labs Responds to Fabricated Allegations from Dissident ShareholderTORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today confirmed that the Company is aware of the news release issued by Apollo Technology Capital Corporation (“Apollo”) on May 29, 2025 making baseless allegations of malfeasance against the Company.
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident PlanTORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today issued a Letter to Shareholders from the Company’s Board of Directors (the “Letter”). The Letter is a response to the amended and restated dissident proxy circular filed by Apollo on May 20, 2025, and in particular Apollo’s plan for the Company. The full text of the Letter to Shareholders follows.
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution AgreementTORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has begun production on novel cannabis metered dose inhalers for the EU and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited (“Blackpoint”), MediPharm’s exclusive sales and distribution partner in those territories.
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with information related to three of the six directors (the “Dissident Nominees”) nominated by Apollo Technology Capital Corporation (“Apollo”) to stand for election at MediPharm’s Annual and Special Meeting of Shareholders on June 16, 2025. All dollar figures in this news release are in U.S. dollars.
MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in JuneTORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the “Purchase Agreement”) for the sale of MediPharm’s facility in Hope, BC, (“Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”).
MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation FilingsTORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today alerted its shareholders to publicly available information about Regan McGee, the controlling shareholder, director, Chairman and CEO of Apollo Technology Capital Corporation (“Apollo”), a dissident MediPharm shareholder. Apollo filed an amended and restated dissident proxy circular on May 20, 2025 (the “Dissident Circular”) seeking to elect Mr. McGee and five other directors to the MediPharm board of directors at the Company’s Annual and Special Meeting of Shareholders scheduled for June 16, 2025 (the “Meeting”).
